Ensemble Discovery

About:

Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.

Website: http://ensemblediscovery.com/

Top Investors: ARCH Venture Partners, Oxford Bioscience Partners, 180 Degree Capital, Flagship Pioneering, CMEA Ventures

Description:

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.